Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 2 Nov 2026
Standard addition

Early Assessment of Circulating Tumor Cells and Their PD-L1 Expression as Predictive Biomarkers in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy: An Exploratory Study

Blood tests measuring tumor cell counts and PD-L1 levels offer real-time monitoring of treatment response in lung cancer without invasive biopsies.

This prospective study evaluated early circulating tumor cell counts and PD-L1 expression as prognostic biomarkers in metastatic NSCLC patients undergoing systemic therapy. CTC PD-L1 assessment offers a minimally invasive strategy for real-time treatment monitoring in NSCLC, where therapeutic benefit remains heterogeneous.

What the study was

Study design
Prospective cohort study
Population
Metastatic NSCLC patients receiving systemic therapy
Category
Early Detection
Maturity
Validated
Journal
ImmunoTargets and therapy

Why it surfaced

Prospective evaluation of CTC PD-L1 as liquid biopsy biomarker in NSCLC; relevant to both early detection surveillance and immunotherapy monitoring.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.